Article

FOLLOW-U; study protocol evaluating oncological systemic treatment response of advanced bladder cancer patients using urinoids

2024-02-05

Abstract excerpt

<title>Abstract</title> <p><italic>Background</italic> Muscle-invasive bladder cancer is an aggressive disease characterized by poor prognosis and high risk for metastases. Neo-adjuvant or induction (in case of node-positive disease) cisplatin-based combination chemotherapy followed by radical cystectomy is recommended for patients with muscle-invasive bladder cancer. However, response rates are highly variable,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f900b54d-2bd2-548a-a266-314a0ca20399
DOI: 10.21203/rs.3.rs-3910661/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

FOLLOW-U; study protocol evaluating oncological systemic treatment response of advanced bladder cancer patients using urinoidsDOI 10.21203/rs.3.rs-3910661/v1Read

Urine-derived bladder cancer organoids (urinoids) as tool for cancer longitudinal response monitoring and therapy adaptationSemantic proximity Read

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Semantic proximity Read

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug ScreeningSemantic proximity Read

Establishing a Canine Urothelial Organoid Repository: A Platform for Comparative and Translational Carcinoma StudiesSemantic proximity Read

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapiesSemantic proximity Read

BioBladder – a national longitudinal sampling study providing a comprehensive framework to precision oncology in urothelial cancerSemantic proximity Read

Guidance of adjuvant instillation in intermediate risk non- muscle invasive bladder cancer by drug screens in patient derived organoids. A Single center, Open-label, Phase II trial. GAIN-INST-TrialSemantic proximity Read

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current DevelopmentSemantic proximity Read

Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancerSemantic proximity Read